Key result
Homozygosity for dominant mutations in muscle channelopathies resulted in much more severe clinical features and CMAP changes compared to heterozygosity.
Why the study?
Does homozygosity for dominant mutations increase the severity of muscle channelopathies compared to heterozygosity?
Observational
Does homozygosity for dominant mutations increase the severity of muscle channelopathies compared to heterozygosity?
Homozygosity for dominant mutations in muscle channelopathies results in a more severe clinical and electrophysiological phenotype than heterozygosity.
No takes yet. Share an insight, caveat, or question.
Homozygosity may worsen channelopathy severity; case report leaves open confirmation in larger cohorts.
Arzel-Hézode et al. (2009) conducted an observational in Muscle channelopathies. Homozygosity for dominant mutations vs. Heterozygosity for dominant mutations was evaluated on Clinical features and compound muscle action potential (CMAP) changes on standardized EMG protocols. Homozygosity for dominant mutations in muscle channelopathies resulted in much more severe clinical features and CMAP changes compared to heterozygosity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: